Solexa Says Invitrogen Reagent Deal Will Give Comfort to Customers as it Sets its Sights on Sales | GenomeWeb
NEW YORK (GenomeWeb News) - Solexa provided some insight last week into how it intends to tackle the next-generation sequencing market in the wake of its OEM reagent agreement with Invitrogen. In a presentation to investors, Solexa CEO John West said that the company has identified around 100 potential customers that it will initially target for its instrument.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.